Combined peptides of human enterovirus 71 protect against virus infection in mice

Vaccine

Volumn 28, Issue 46, 2010, Pages 7444-7451

  Liu, Jiang Ning ^a   Wang, Wei ^b   Duo, Jian Ying ^b   Hao, Yi ^b   Ma, Chun Mei ^b   Li, Wan Bo ^a   Lin, Shu Zhu ^a   Gao, Xue Zhong ^c   Liu, Xiao Lin ^c   Xu, Yan Feng ^a   Xu, Wen Bo ^d   Qin, Chuan ^a,b   Zhang, Lian Feng ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^c Fuyang People's Hospital   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Combined peptides; EV71; Vaccine

Indexed keywords

PEPTIDE VACCINE; POLYPEPTIDE[P444-565]; POLYPEPTIDE[P444-565][P566-665]; POLYPEPTIDE[P444-565][P746-876]; POLYPEPTIDE[P566-665]; POLYPEPTIDE[P70-159][P140-249][P324-443][P746-876] VACCINE; POLYPEPTIDE[P746-876]; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENTEROVIRUS 71; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRAIN; CROSS REACTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; HUMANS; INFANT; MALE; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; PEPTIDES; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 77958165096     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.080     Document Type: Article

References (58)

1. Brown B.A., Pallansch M.A. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 1995, 39(2-3):195-205.
2. Deibel R., Gross L.L., Collins D.N. Isolation of a new enterovirus (38506). Proc Soc Exp Biol Med 1975, 148(1):203-207.
3. AbuBakar S., Sam I.C., Yusof J., Lim M.K., Misbah S., MatRahim N., et al. Enterovirus 71 outbreak, Brunei. Emerg Infect Dis 2009, 15(1):79-82.
4. Chan L.G., Parashar U.D., Lye M.S., Ong F.G., Zaki S.R., Alexander J.P., et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 2000, 31(3):678-683.
5. Chang L.Y. Enterovirus 71 in Taiwan. Pediatr Neonatol 2008, 49(4):103-112.
6. Liu C.C., Tseng H.W., Wang S.M., Wang J.R., Su I.J. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 2000, 17(1):23-30.
7. Shah V.A., Chong C.Y., Chan K.P., Ng W., Ling A.E. Clinical characteristics of an outbreak of hand, foot and mouth disease in Singapore. Ann Acad Med Singapore 2003, 32(3):381-387.
8. van der Sanden S., Koopmans M., Uslu G., van der Avoort H. Epidemiology of enterovirus 71 in the Netherlands, 1963-2008. J Clin Microbiol 2009, 47(9):2826-2833.
9. Chang L.Y., Huang L.M., Gau S.S., Wu Y.Y., Hsia S.H., Fan T.Y., et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 2007, 356(12):1226-1234.
10. Chang L.Y., Lee C.Y., Kao C.L., Fang T.Y., Lu C.Y., Lee P.I., et al. Hand, foot and mouth disease complicated with central nervous system involvement in Taiwan in 1980-1981. J Formos Med Assoc 2007, 106(2):173-176.
11. Chang L.Y., Lin T.Y., Hsu K.H., Huang Y.C., Lin K.L., Hsueh C., et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999, 354(9191):1682-1686.
12. Abubakar S., Chee H.Y., Shafee N., Chua K.B., Lam S.K. Molecular detection of enteroviruses from an outbreak of hand, foot and mouth disease in Malaysia in 1997. Scand J Infect Dis 1999, 31(4):331-335.
13. Ang L.W., Koh B.K., Chan K.P., Chua L.T., James L., Goh K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009, 38(2):106-112.
14. Ding N.Z., Wang X.M., Sun S.W., Song Q., Li S.N., He C.Q. Appearance of mosaic enterovirus 71 in the 2008 outbreak of China. Virus Res 2009, 145(1):157-161.
15. Hosoya M., Kawasaki Y., Sato M., Honzumi K., Kato A., Hiroshima T., et al. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J 2006, 25(8):691-694.
16. Li L., He Y., Yang H., Zhu J., Xu X., Dong J., et al. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol 2005, 43(8):3835-3839.
17. Yang F., Ren L., Xiong Z., Li J., Xiao Y., Zhao R., et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 2009, 47(7):2351-2352.
18. Henke A., Zell R., Stelzner A. DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice. Antiviral Res 2001, 49(1):49-54.
19. Chen H.F., Chang M.H., Chiang B.L., Jeng S.T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 2006, 24(15):2944-2951.
20. Chen H.L., Huang J.Y., Chu T.W., Tsai T.C., Hung C.M., Lin C.C., et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008, 26(23):2882-2889.
21. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26(15):1855-1862.
22. Wu T.C., Wang Y.F., Lee Y.P., Wang J.R., Liu C.C., Wang S.M., et al. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 2007, 81(19):10310-10315.
23. Chen C.S., Yao Y.C., Lin S.C., Lee Y.P., Wang Y.F., Wang J.R., et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol 2007, 81(17):8996-9003.
24. Jia C.S., Liu J.N., Li W.B., Ma C.M., Lin S.Z., Hao Y., Gao X.Z., Liu X.L., Xu Y.F., Zhang L.F., Qin C. The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J 2010, 7(47).
25. Lin Y.C., Wu C.N., Shih S.R., Ho M.S. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 2002, 20(19-20):2485-2493.
26. He Y.Q., Yang H., Li L.L., Tan J., Zhou L., Mao L.S., et al. Genotype analysis of enterovirus type 71 detected from patients with hand-foot-mouth disease in Shenzhen. Zhonghua Liu Xing Bing Xue Za Zhi 2008, 29(8):790-793.
27. Arita M., Ami Y., Wakita T., Shimizu H. Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol 2008, 82(4):1787-1797.
28. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
29. Zhang Y., Tan X.J., Wang H.Y., Yan D.M., Zhu S.L., Wang D.Y., et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009, 44(4):262-267.
30. Yang C.F., De L., Yang S.J., Ruiz Gomez J., Cruz J.R., Holloway B.P., et al. Genotype-specific in vitro amplification of sequences of the wild type 3 polioviruses from Mexico and Guatemala. Virus Res 1992, 24(3):277-296.
31. Yang Z.H., Zhu Q.R., Li X.Z., Wang X.H., Wang J.S., Hu J.Y., et al. Detection of enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Shanghai, 2002. Zhonghua Er Ke Za Zhi 2005, 43(9):648-652.
32. Kao S.J., Yang F.L., Hsu Y.H., Chen H.I. Mechanism of fulminant pulmonary edema caused by enterovirus 71. Clin Infect Dis 2004, 38(12):1784-1788.
33. Yang Y., Wang H., Gong E., Du J., Zhao X., McNutt M.A., et al. Neuropathology in 2 cases of fatal enterovirus type 71 infection from a recent epidemic in the People's Republic of China: a histopathologic, immunohistochemical, and reverse transcription polymerase chain reaction study. Hum Pathol 2009, 40(9):1288-1295.
34. He S.J., Chen D., Zheng X.Q., Wang C.X., Huang A.R., Jin Y.M., et al. Three cases of enterovirus 71 infection with pulmonary edema or pulmonary hemorrhage as the early clinical manifestation. Zhonghua Er Ke Za Zhi 2008, 46(7):513-516.
35. Arita M., Nagata N., Iwata N., Ami Y., Suzaki Y., Mizuta K., et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 2007, 81(17):9386-9395.
36. Hashimoto I., Hagiwara A., Kodama H. Neurovirulence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, foot and mouth disease. Arch Virol 1978, 56(3):257-261.
37. Chang L.Y., Hsiung C.A., Lu C.Y., Lin T.Y., Huang F.Y., Lai Y.H., et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 2006, 60(4):466-471.
38. Wang S.M., Lei H.Y., Yu C.K., Wang J.R., Su I.J., Liu C.C. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 2008, 198(7):1002-1006.
39. Yang K.D., Yang M.Y., Li C.C., Lin S.F., Chong M.C., Wang C.L., et al. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis 2001, 183(6):850-856.
40. Atkinson M.A., Bowman M.A., Campbell L., Darrow B.L., Kaufman D.L., Maclaren N.K. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994, 94(5):2125-2129.
41. Cram D.S., Faulkner-Jones B., Kun J., Harrison L.C. Glutamic acid decarboxylase-67 (GAD67): expression relative to GAD65 in human islets and mapping of autoantibody epitopes. Endocrinology 1995, 136(3):1111-1119.
42. Seissler J., de Sonnaville J.J., Morgenthaler N.G., Steinbrenner H., Glawe D., Khoo-Morgenthaler U.Y., et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998, 41(8):891-897.
43. Taplin C.E., Barker J.M. Autoantibodies in type 1 diabetes. Autoimmunity 2008, 41(1):11-18.
44. Arnson Y., Amital H., Guiducci S., Matucci-Cerinic M., Valentini G., Barzilai O., et al. The role of infections in the immunopathogensis of systemic sclerosis-evidence from serological studies. Ann N Y Acad Sci 2009, 1173:627-632.
45. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80(5):695-705.
46. Grigoriadis N., Hadjigeorgiou G.M. Virus-mediated autoimmunity in multiple sclerosis. J Autoimmune Dis 2006, 3:1.
47. van Drunen Littel-van den Hurk S., Mapletoft J.W., Arsic N., Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007, 17(1):5-34.
48. Foo D.G., Ang R.X., Alonso S., Chow V.T., Quak S.H., Poh C.L. Identification of immunodominant VP1 linear epitope of enterovirus 71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in Western blots. Clin Microbiol Infect 2008, 14(3):286-288.
49. Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20(5-6):895-904.
50. Chiu C.H., Chu C., He C.C., Lin T.Y. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 2006, 8(7):1671-1678.
51. Ong K.C., Badmanathan M., Devi S., Leong K.L., Cardosa M.J., Wong K.T. Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol 2008, 67(6):532-542.
52. Wang Y.F., Chou C.T., Lei H.Y., Liu C.C., Wang S.M., Yan J.J., et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 2004, 78(15):7916-7924.
53. Jia C.S., Liu J.N., Li W.B., Ma C.M., Lin S.Z., Hao Y., et al. The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J 2010, 7(1):47.
54. Foo D.G., Alonso S., Chow V.T., Poh C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007, 9(11):1299-1306.
55. Bible J.M., Iturriza-Gomara M., Megson B., Brown D., Pantelidis P., Earl P., et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol 2008, 46(10):3192-3200.
56. Chan Y.F., Sam I.C., Abubakar S. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 2009, 10(3):404-412.
57. Chua K.B., Chua B.H., Lee C.S., Chem Y.K., Ismail N., Kiyu A., et al. Genetic diversity of enterovirus 71 isolated from cases of hand, foot and mouth disease in the 1997, 2000 and 2005 outbreaks, Peninsular Malaysia. Malays J Pathol 2007, 29(2):69-78.
58. Chen K.T., Chang H.L., Wang S.T., Cheng Y.T., Yang J.Y. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 2007, 120(2):e244-e252.